
Join to view full profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Haesun Choi, MD is a board certified nuclear medicine physician in Houston, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Iowa. She is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
USA HealthResidency, Radiology-Diagnostic, 1987 - 1989
University of Iowa Health Care Medical CenterResidency, Nuclear Medicine, 1984 - 1987
Hanyang University College of MedicineClass of 1979
Certifications & Licensure
TX State Medical License 1992 - 2028
IA State Medical License 1984 - 2005
IA State Medical License 1984 - 2005
AL State Medical License 1988 - 2001
American Board of Nuclear Medicine Nuclear Medicine
American Board of Radiology Diagnostic Radiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Publications & Presentations
PubMed
- 19 citationsRepeatability and Reproducibility Assessment of the Apparent Diffusion Coefficient in the Prostate: A Trial of the ECOG-ACRIN Research Group (ACRIN 6701).Michael A Boss, Bradley S Snyder, Eunhee Kim, Dena Flamini, Sarah Englander
Journal of Magnetic Resonance Imaging. 2022-09-01 - 2 citationsImpact of MRI/US fusion-guided prostate biopsy on biopsy-naïve patients: A single urologist's experience.Muammer Altok, Cihan Demirel, Hyunseon C Kang, Haesun Choi, David John
BJUI Compass. 2022-01-01 - 127 citationsDefinitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trialChad Tang, Pavlos Msaouel, Kieko Hara, Haesun Choi, Venus Le
The Lancet. Oncology. 2021-10-28
Press Mentions
Tumor Response Criteria for Assessing Pazopanib First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)June 1st, 2020